Skip to content

MEREO BIOPHARMA GROUP PLC

MREO

CIK 0001719714

← back to feed
Revenue (TTM)
$500K
Q1 May 2026
Net Income (TTM)
−$41.25M
+3.2% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.06
+16.7% YoY Q1 May 2026
Gross Margin
287.2%
Q1 May 2026
Operating Margin
-8,096.4%
Q1 May 2026
Net Margin
-8,249.2%
Q1 May 2026
Free Cash Flow (TTM)
−$29.9M
Q1 May 2026
Cash
$36.22M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
798.09M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings